Compare BridgeBio Pharma Inc (BBIO) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Simon Property Group Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Simon Property Group Inc trades at $219.28 (market cap $71.52B). The key difference: Simon Property Group Inc is far larger — about 4.3× BridgeBio Pharma Inc's market cap, and Simon Property Group Inc pays a 3.99% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SPG | |
|---|---|---|
Market Cap | $16.61B | $71.52B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $236.70 |
52-Week Low | $47.29 | $169.22 |
Enterprise Value | $18.16B | $100.00B |
Dividend Yield | — | 3.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Simon Property Group (SPG) trades at $222.91, up 0.49% on the day, near its consensus price target of $223.50. The stock shows strong fundamentals with a P/E of 15.5 and robust profitability, including a net income margin of 70.59% and ROE of 127.05%. Recent Q2 2026 earnings beat expectations with FFO of $3.29 per share, driven by leasing momentum and raised guidance. Technical indicators are bearish overall, with support at $221 and resistance at $224. The company maintains a solid dividend, paying $2.25 in H1 2026.
Outlook: SPG benefits from strong operational performance and raised 2026 guidance, supported by tenant demand and property NOI growth. Investment opportunities include consistent earnings beats and a high ROE. Risks involve elevated long-term debt of $24.21 billion, potential interest rate pressures, and e-commerce competition. Analyst sentiment is mixed with 40.54% buy ratings, but technical bearish signals suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
